Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
18.28
+0.18 (0.99%)
At close: Feb 11, 2026, 4:00 PM EST
18.21
-0.07 (-0.39%)
After-hours: Feb 11, 2026, 7:32 PM EST
Takeda Pharmaceutical Revenue
Takeda Pharmaceutical had revenue of 1.19T JPY in the quarter ending December 31, 2025. This brings the company's revenue in the last twelve months to 4.52T, down -5.56% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4.52T JPY
Revenue Growth
-5.56%
P/S Ratio
2.01
Revenue / Employee
95,203,877 JPY
Employees
47,455
Market Cap
57.17B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | 326.69B | 18.45% |
| Mar 31, 2018 | 1.77T | 38.48B | 2.22% |
| Mar 31, 2017 | 1.73T | -75.33B | -4.17% |
| Mar 31, 2016 | 1.81T | 29.55B | 1.66% |
| Mar 31, 2015 | 1.78T | 86.14B | 5.09% |
| Mar 31, 2014 | 1.69T | 134.68B | 8.65% |
| Mar 31, 2013 | 1.56T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Haleon | 15.10B |
| Viatris | 14.12B |
| Zoetis | 9.40B |
| Elanco Animal Health | 4.59B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.13B |
| Amneal Pharmaceuticals | 2.93B |
TAK News
- 1 day ago - U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 - Business Wire
- 2 days ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 2 days ago - Takeda deepens AI drug discovery push with $1.7 billion Iambic deal - Reuters
- 2 days ago - Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules - Business Wire
- 6 days ago - Japanese drugmakers slump after Trump unveils discount drug website - Reuters
- 12 days ago - Takeda Tests New Highs, But Struggles To Find Entyvio Successor - Seeking Alpha
- 13 days ago - Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead - Business Wire